BioCryst Pharmaceuticals: Enter Now Before The End Of Next September 2020

On August 6, BioCryst Pharmaceuticals(NASDAQ:BCRX)reported Q2 results. We were all hoping to find some data from part 1 of the Galidesivir trial that is being conducted in Brazil to evaluate efficacy and safety as a treatment against COVID-19. However, the Company has only briefly commented that everything is going according to plan and that, until the end of the third quarter (next September), they will not give any information about part 1 of the trial.
The only remarkable thing about Galides…

Click here to view the original article.